<document xmlns="http://cnx.rice.edu/cnxml">
  <title>Drugs Affecting the Renin-Angiotensin-Aldosterone System</title>
  <metadata xmlns:md="http://cnx.rice.edu/mdml">
    <md:title>Drugs Affecting the Renin-Angiotensin-Aldosterone System</md:title>
    <md:content-id>m00295</md:content-id>
    <md:uuid>9c3a886c-f4fa-402e-b9db-c8e22ffe7328</md:uuid>
  </metadata>
<content>
<section class="learning-objectives" id="sect-00001">
<title>Learning Outcomes</title>
<para id="para-00001">By the end of this section, you should be able to:</para>
<list id="list-00001"> 
<item>Identify the characteristics of drugs affecting the renin-angiotensin-aldosterone system that are used to treat heart failure.</item>
<item>Explain the indications, actions, adverse reactions, and interactions of drugs affecting the renin-angiotensin-aldosterone system that are used to treat heart failure.</item>
<item>Describe nursing implications of drugs affecting the renin-angiotensin-aldosterone system that are used to treat heart failure.</item>
<item>Explain the client education related to drugs affecting the renin-angiotensin-aldosterone system that are used to treat heart failure.</item></list>
</section>
<section id="sect-00003">
<title>Angiotensin-Converting (ACE) Enzyme Inhibitors</title>
<para id="para-00002">As mentioned in <link document="m00313">Antihypertensive and Antianginal Drugs</link>, <term id="term-00001">angiotensin-converting enzyme (ACE) inhibitors</term> are a classification of drugs that block the body’s production of angiotensin II. Angiotensin II is one of the products of the <term id="term-00002">renin-angiotensin-aldosterone system (RAAS)</term> (see <link target-id="fig-00001" document="m00295"/>), and it stimulates multiple end-organ effects. Two of these effects that are important in heart failure are constriction of arterioles and sodium and water retention of the kidneys. Vasoconstriction causes increased afterload, and sodium and water retention cause increased preload. In heart failure, the heart is already struggling to maintain an adequate cardiac output. Both increased afterload and increased preload will make this task more difficult. ACE inhibitors have been shown to decrease morbidity and mortality in clients with heart failure (Heidenreich et al., 2022).</para>
<figure id="fig-00001">
<media alt="A diagram shows the renin-angiotensin-aldosterone system, which produces angiotensin 2. Direct effects of angiotensin 2 are arteries constricting, which increases cardiac output, resulting in an increase in blood pressure and volume; decreased  glomerular filtration rate, resulting in water retention; and increased thirst.  Renin helps angiotensinogen turn into angiotensin 1. ACE helps angiotensin 1 become angiotensin 2. Angiotensin 2 produces aldosterone and ADH. Aldosterone causes nephron distal tubules to reabsorb sodium  and water, which increases blood volume. ADH mediates insertion of aquaporins into nephron collecting duct cells, resulting in more water being reabsorbed into the blood. It also increases sodium reabsorption in the medulla of the kidney.">
<image mime-type="image/jpeg" src="../../media/PHA_Figure_19_02_004.png"/></media>
<caption>The renin-angiotensin-aldosterone system produces angiotensin II, which constricts arterioles and increases sodium and water retention in the kidneys. (attribution: Copyright Rice University, OpenStax, under CC BY 4.0 license)</caption>
</figure>
<para id="para-00003">ACE inhibitors are used in the management of both hypertension and heart failure. <link target-id="table-00001" document="m00295"/> lists common ACE inhibitors used in the management of heart failure and typical routes and dosing for adult clients. A comprehensive list of ACE inhibitors can be found in <link document="m00313">Antihypertensive and Antianginal Drugs</link>.</para>
      <table class="vertically-tight full-width" id="table-00001">
     <tgroup cols="2">
      <colspec colnum="1" colname="c1" colwidth="1*"/>
      <colspec colnum="2" colname="c2" colwidth="2*"/>
     <thead>
      <row>
      <entry valign="top" align="center"><span class="blue-text">Drug</span></entry>
      <entry valign="top" align="center"><span class="blue-text">Routes and Dosage Ranges</span></entry>
      </row>
      </thead>
      <tbody>
      <row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00003">Captopril</term><newline/>
(<term class="no-emphasis" id="term-00004">Capto</term>)</entry>
<entry valign="middle" align="left">6.25–50 mg orally 3 times daily.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00005">Enalapril</term><newline/>
(<term class="no-emphasis" id="term-00006">Vasotec</term>)</entry>
<entry valign="middle" align="left">2.5–20 mg orally twice daily.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00007">Fosinopril</term><newline/>
(<term class="no-emphasis" id="term-00008">Monopril</term>)</entry>
<entry valign="middle" align="left">5–40 mg orally daily.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00009">Lisinopril</term><newline/>
(<term class="no-emphasis" id="term-00010">Zestril</term>)</entry>
<entry valign="middle" align="left">2.5–40 orally mg daily.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00011">Quinapril</term><newline/>
(<term class="no-emphasis" id="term-00012">Accupril</term>)</entry>
<entry valign="middle" align="left">5–20 mg orally twice daily.</entry>
</row>
      </tbody>
     </tgroup>
<caption><emphasis effect="bold">Drug Emphasis Table: ACE Inhibitors</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
      </table>


<note class="special-considerations" id="note-00001">
<title>ACE Inhibitors</title>
<para id="para-00004"><term class="no-emphasis" id="term-00013">Black clients with hypertension</term> demonstrate a lower response to ACE inhibitor monotherapy. ACE inhibitors interfere with the renin-angiotensin-aldosterone system, which causes high blood pressure when renin levels are high. Black clients often have hypertension but also have lower levels of renin. Therefore, concomitant therapy may be required to increase response to antihypertensive therapies.</para>
<para id="para-00005">(Source: Astra Zeneca, 2012)</para>
</note>
<section id="sect-00004">
<title>Adverse Effects and Contraindications</title>
<para id="para-00006">ACE inhibitors are relatively safe to use and have a low incidence of serious adverse effects. Adverse effects include angioedema, non-productive cough, neutropenia (low neutrophils in the blood), agranulocytosis (low granulocytes in the blood), proteinuria (protein in the urine), and rash. Hypotension may develop. Clients may develop an ACE inhibitor–associated cough (a persistent, dry, itchy cough). Hyperkalemia (elevated potassium level in the blood) may develop. </para>
<para id="para-00007">ACE inhibitors cause fetal toxicity and should be immediately discontinued if pregnancy occurs. Clients with renal impairment should use cautiously. Clients with a previous hypersensitivity reaction to an ACE inhibitor should not be prescribed this classification of drug.</para>

<para id="para-00008"><link target-id="table-00002" document="m00295"/> is a drug prototype table for ACE inhibitors featuring lisinopril. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>

<table class="vertically-tight" id="table-00002">
<tgroup cols="2">
<colspec colnum="1" colname="col1" colwidth="1*"/>
<colspec colnum="2" colname="col2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top">
<emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
Angiotensin-converting enzyme (ACE) inhibitor<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
Inhibits the enzyme that converts angiotensin I to angiotensin II and thereby suppresses the renin-angiotensin-aldosterone system</entry>
<entry valign="top">
<emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
2.5–40 mg orally twice daily.</entry>
</row>
<row>
<entry valign="top"><emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
Hypertension<newline/>
Heart failure<newline/>
Reduction of mortality in acute myocardial infarction<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
Lowers blood pressure<newline/>
Increases blood supply and oxygen to the heart</entry>

<entry valign="top"><emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
Aliskiren<newline/>
Lithium<newline/>
Sacubitril<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
Alcohol<newline/>
Tobacco</entry>
</row>
<row>
<entry valign="top"><emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
Angioedema<newline/>
Hyperkalemia<newline/>
Fatigue<newline/>
Orthostatic hypotension<newline/>
Asthenia<newline/>
Diarrhea<newline/>
Nausea/vomiting<newline/>
Headache<newline/>
Dizziness/vertigo<newline/>
Cough<newline/>
Rash<newline/>
Abdominal pain<newline/>
Angina</entry>

<entry valign="top">
<emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
Hypersensitivity<newline/>
History of angioedema<newline/>
Pregnancy (fetal toxicity)<newline count="2"/>

Caution:<newline/>
Aortic stenosis<newline/>
Diabetes<newline/>
Syncope<newline/>
Orthostatic hypotension<newline/>
Impaired renal function<newline/>
Breastfeeding</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype Table: Lisinopril</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
</section>
<section id="sect-00005">
<title>Nursing Implications</title>
<para id="para-00009">The nurse should do the following for clients who are taking ACE inhibitors:</para>
<list id="list-00002">
<item>Assess the client’s blood pressure and pulse on an ongoing basis with initial dosing and intermittently during drug therapy. </item>
<item>Assess and monitor the client for adverse effects, drug and food interactions, and contraindications. </item>
<item>Provide client teaching regarding the drug and when to call the health care provider. See below for client teaching guidelines.</item>
</list>
<note class="safety-alert" id="note-00002">
<title>ACE Inhibitors</title>
<para id="para-00010">Taking ACE inhibitors with potassium-containing salt substitutes or consuming large amounts of high-potassium foods increases the risk of hyperkalemia. Having a blood potassium level above 6.0 mmol/L is considered a medical emergency and can result in cardiac arrest.</para>
<para id="para-00011">Clients of childbearing age should take measures not to become pregnant while taking ivabradine due to teratogenic effects (causing harm to embryo or fetus).</para>
</note>
<note class="client-teaching" id="note-00003">
<para id="para-00012"><emphasis effect="bold">The client taking an ACE inhibitor should:</emphasis></para>
<list list-type="bulleted" id="list-00003">
<item>Avoid foods high in potassium and salt substitutes (because these are high in potassium) due to the aldosterone release.</item>
<item>Report side effects such as cough, angioedema, or anaphylactic reactions to their health care provider.</item>
<item>Notify their health care provider if they experience abdominal pain, joint or muscle aches, muscle weakness, change in the amount of urine produced, or trouble breathing. </item>
<item>Be aware that a persistent cough may develop when taking ACE inhibitors. </item>
<item>Notify their health care provider if pregnant, planning on getting pregnant, or breastfeeding prior to starting an ACE inhibitor. </item>
<item>Report symptoms such as chest pain, slurred speech, hemiparesis, and difficulty speaking or walking to their health care provider immediately because these may be symptoms of a heart attack or stroke.</item>
<item>Notify their health care provider about symptoms such as dizziness, lightheadedness, or fainting because these could be related to low blood pressure.</item>
</list>
</note>
</section>
</section>
<section id="sect-00006">
<title>Angiotensin II Receptor Blockers</title>
<para id="para-00013"><term id="term-00014">Angiotensin II receptor blockers (ARBs)</term> are a classification of drugs that bind to and inhibit angiotensin II type I receptors. ARBs work directly at the receptor site to block angiotensin II from binding with receptors on the cells (see <link target-id="fig-00001" document="m00295"/>). The effect of ARBs is similar to that of ACE inhibitors; however, the side effects are lessened. This means that the potential for angioedema is decreased. Also, there is no side effect of cough.</para>
<para id="para-00014">Angiotensin II receptor blockers decrease blood pressure and therefore decrease afterload. This is beneficial in treating heart failure since decreased afterload means the heart does not have to work as hard to generate stroke volume.</para>
<para id="para-00015"><link target-id="table-00003" document="m00295"/> lists common ARBs used in the management of heart failure and typical routes and dosing for adult clients. A comprehensive list of ARBs can be found in <link document="m00313">Antihypertensive and Antianginal Drugs</link>.</para>
<table class="vertically-tight full-width" id="table-00003">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="2*"/>
<thead>
<row>
      <entry valign="top" align="center"><span class="blue-text">Drug</span></entry>
      <entry valign="top" align="center"><span class="blue-text">Routes and Dosage Ranges</span></entry>
</row>
</thead>
<tbody>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00015">Candesartan</term><newline/>
(<term class="no-emphasis" id="term-00016">Atacand</term>)</entry>
<entry valign="top" align="left">4 mg orally daily; maximum dose: 32 mg daily.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00017">Losartan</term><newline/>
(<term class="no-emphasis" id="term-00018">Cozaar</term>)</entry>
<entry valign="top" align="left">25–150 orally mg daily.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00019">Valsartan</term><newline/>
(<term class="no-emphasis" id="term-00020">Diovan</term>)</entry>
<entry valign="top" align="left">20–160 orally mg daily.</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Emphasis Table: ARBs</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
<section id="sect-00007">
<title>Adverse Effects and Contraindications</title>
<para id="para-00016">Adverse effects of ARBs include dizziness, muscle cramps, weakness, heartburn, diarrhea, leg swelling, headaches, and weight loss. Serious adverse effects include angioedema, hypotension, hepatic impairment, and hyperkalemia.</para>
<para id="para-00017">ARBs cause fetal toxicity and should not be taken during pregnancy. Clients with hepatic impairment should use ARBs cautiously. Clients with a previous hypersensitivity reaction or angioedema to an ARB inhibitor should not be prescribed this classification of drug. Clients with a history of mood disturbances or who are at risk for mood disturbances should be monitored closely for suicidal ideation.</para>
<para id="para-00018"><link target-id="table-00004" document="m00295"/> is a drug prototype table for ARBs featuring losartan. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00004">
<tgroup cols="2">
<colspec colnum="1" colname="col1" colwidth="1*"/>
<colspec colnum="2" colname="col2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top">
<emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
Angiotensin II receptor blocker (ARB)<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
Blocks the binding of angiotensin II to the angiotensin I receptor, thereby decreasing vasoconstriction and lowering blood pressure</entry>

<entry valign="top">
<emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
25–150 mg orally daily.</entry>
</row>
<row>
<entry valign="top"><emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
Hypertension<newline/>
Heart failure<newline/>
Nephropathy in clients with type 2 diabetes<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
Lowers blood pressure<newline/>
Increases blood supply and oxygen to the heart</entry>

<entry valign="top">
<emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
Aliskiren<newline/>
Lithium<newline/>
Potassium-sparing diuretics (may increase hyperkalemia)<newline count="2"/>

<emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
Alcohol<newline/>
Tobacco</entry>
</row>
<row>
<entry valign="top">
<emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
Hyperkalemia<newline/>
Dizziness<newline/>
Syncope<newline/>
Increased thirst<newline/>
Decreased urinary output<newline/>
Irregular heartbeat<newline/>
Angioedema</entry>
<entry valign="top">
<emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
Hypersensitivity<newline/>
Pregnancy (fetal toxicity)<newline count="2"/>

Caution:<newline/>
Hepatic impairment<newline/>
Renal impairment<newline/>
Hypotension<newline/>
Hypovolemia<newline/>
Hyperkalemia</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype Table: Losartan</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
<note class="special-considerations" id="note-00004">
<title>ARBs</title>
<para id="para-00019">The RAAS has been associated with increased risk of mood disorders. The use of ARBs may be associated with an increased risk of suicide compared with other antihypertensive therapies.</para>
<para id="para-00020"><term class="no-emphasis" id="term-00021">Black clients</term> with hypertension demonstrate a lower response to ARB monotherapy. Concomitant therapy may be required to increase response to antihypertensive therapies.</para>
<para id="para-00021"><term class="no-emphasis" id="term-00022">Older adults</term> and clients with hepatic impairment should start on a low initial dose because the drug is metabolized by the liver.</para>
<para id="para-00022">(Source: Colvin et al., 2020)</para>
</note>
</section>
<section id="sect-00008">
<title>Nursing Implications</title>
<para id="para-00023">The nurse should do the following for clients who are taking ARBs:</para>
<list id="list-00004">
<item>Monitor the client’s blood pressure as prescribed. </item>
<item>Monitor the client for interactions because many medications and herbal supplements interact with ARBs. </item>
<item>Monitor the client for adverse effects, including electrolyte imbalances and alterations in liver and renal function. </item>
<item>Provide client teaching regarding the drug and when to call the health care provider. See below for client teaching guidelines.</item>
</list>
<note class="client-teaching" id="note-00005">
<para id="para-00024"><emphasis effect="bold">The client taking an ARB should:</emphasis></para>
<list list-type="bulleted" id="list-00005">
<item>Avoid foods high in potassium and salt substitutes (because these substitute potassium for sodium) due to the aldosterone release. </item>
<item>Report side effects such as cough, angioedema, or anaphylactic reactions to the health care provider. </item>
<item>Notify their health care provider if they experience abdominal pain, joint or muscle aches, muscle weakness, change in the amount of urine produced, or trouble breathing. </item>
<item>Notify their health care provider if pregnant, planning on getting pregnant, or breastfeeding prior to starting an ARB.</item>
<item>Notify their health care provider about symptoms such as dizziness, lightheadedness, or fainting because these could be related to low blood pressure.</item>
</list>
</note>
</section>
</section>
<section id="sect-00009">
<title>Angiotensin Receptor/Neprilysin Inhibitors</title>
<para id="para-00025">Recently, a new classification of heart failure medication was developed, <term id="term-00023">angiotensin receptor/neprilysin inhibitors (ARNIs)</term>. This combination medication is a first-line medication for many classifications of heart failure. It is a combination of an ARB and a new type of medication, a neprilysin inhibitor. There currently is only one medication in the ARNI class: <term class="no-emphasis" id="term-00024">sacubitril/valsartan</term> (<term class="no-emphasis" id="term-00025">Entresto</term>).</para>
<para id="para-00026">In heart failure with reduced ejection fraction, there is a lot of stress on the left ventricle as well as left ventricular dilation. This is due to an increased preload. When the ventricle dilates to a point that is no longer helpful to the heart, the myocytes release brain natriuretic peptide (BNP). BNP stimulates a compensatory mechanism that leads to vasodilation and decreased sodium and water absorption. Vasodilation and diuresis decrease afterload and preload, which makes the workload of the heart decrease.</para>
<para id="para-00027">Neprilysin is an enzyme that breaks down BNP. The inhibition of neprilysin means that BNP can stay in the body’s circulatory system longer. If BNP stays in the system longer, then vasodilation and decreased sodium and water reabsorption will last longer, which will decrease afterload and preload. This will decrease the workload of the heart.</para>
<section id="sect-00010">
<title>Adverse Effects and Contraindications</title>
<para id="para-00028">Adverse effects of ARNIs include angioedema, hypotension, renal impairment, and hyperkalemia.</para>
<para id="para-00029">ARNIs contain ARBs and cause fetal toxicity; they should not be taken during pregnancy. Clients with hepatic impairment should use ARNIs cautiously. Clients with a previous hypersensitivity or angioedema reaction to an ARB inhibitor should not be prescribed this classification of drug. Clients with a history of mood disturbances or who are at risk for mood disturbances should be monitored closely for suicidal ideation.</para>
<note class="clinical-tip" id="note-00006">
<title>Reviewing Medications</title>
<para id="para-00030">It is important for the nurse to review all of a client’s medications. Clients should not take ACE inhibitors, ARBs, or ARNIs at the same time. Clients should be prescribed only one of these classifications of medication at a time.</para>
</note>
<para id="para-00031"><link target-id="table-00005" document="m00295"/> is a drug prototype table for angiotensin receptor/neprilysin inhibitors featuring sacubitril/valsartan. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00005">
<tgroup cols="2">
<colspec colnum="1" colname="col1" colwidth="1*"/>
<colspec colnum="2" colname="col2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top">
<emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
Angiotensin receptor/neprilysin inhibitor<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
Causes angiotensin receptor blockade and inhibition of the enzyme that breaks down BNP</entry>
<entry valign="top">
<emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
Initial dose: 49 mg/51 mg orally twice daily; maximum dose: 97 mg/103 mg twice daily.</entry>
</row>
<row>
<entry valign="top"><emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
Heart failure<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
Vasodilation</entry>
<entry valign="top">
<emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
Potassium-sparing diuretics (may lead to increased serum potassium)<newline/>
Nonsteroidal anti-inflammatory drugs (NSAIDs; may lead to increased risk of renal impairment)<newline/>
Lithium (increased risk of lithium toxicity)<newline/>
ACE inhibitors (increased risk of angioedema)<newline count="2"/>

<emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
No significant interactions</entry>
</row>
<row>
<entry valign="top">
<emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
Angioedema<newline/>
Hypotension<newline/>
Hyperkalemia<newline/>
Cough<newline/>
Dizziness<newline/>
Renal failure</entry>
<entry valign="top">
<emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
Pregnancy (fetal toxicity)<newline/>
History of angioedema with ACE inhibitor or ARB therapy</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype Table: Sacubitril/Valsartan</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
</section>
<section id="sect-00011">
<title>Nursing Implications</title>
<para id="para-00032">The nurse should do the following for clients who are taking ARNIs:</para>
<list id="list-00006">
<item>Monitor the client’s blood pressure as prescribed.</item>
<item>Monitor the client for medication and herbal supplement interactions.</item>
<item>Report adverse effects, including electrolyte imbalances and alterations in liver and renal function, to the health care provider.</item>
<item>Provide client teaching regarding the drug and when to call the health care provider. See below for client teaching guidelines.</item>
</list>
<note class="client-teaching" id="note-00007">
<para id="para-00033"><emphasis effect="bold">The client taking an ARNI should:</emphasis></para>
<list list-type="bulleted" id="list-00007">
<item>Avoid foods high in potassium and salt substitutes (because these are high in potassium) due to the aldosterone release.</item>
<item>Report side effects such as cough, angioedema, and anaphylactic reactions to the health care provider.</item>
<item>Notify their health care provider if they experience abdominal pain, joint or muscle aches, muscle weakness, change in the amount of urine produced, or trouble breathing.</item>
<item>Notify their health care provider if pregnant, planning on getting pregnant, or breastfeeding prior to starting an ARNI.</item>
<item>Notify their health care provider about symptoms such as dizziness, lightheadedness, or fainting because these could be related to low blood pressure.</item>
</list>
</note>
</section>
</section>
<section id="sect-00012">
<title>Mineralocorticoid Receptor Antagonists</title>
<para id="para-00034"><term id="term-00026">Mineralocorticoid receptor antagonists (MRAs)</term> (also known as <term class="no-emphasis" id="term-00027">aldosterone antagonists</term>) are often categorized as diuretics because they ultimately do cause diuresis. When the RAAS is activated, one of the end results is the stimulation of the adrenal glands to secrete aldosterone. (See <link target-id="fig-00001" document="m00295"/> earlier in the chapter.) Aldosterone binds to receptors on cells in the distal tubule of the nephron, which then causes them to reabsorb sodium and water. During this process, potassium secretion increases. Aldosterone antagonists block the receptor so that aldosterone can’t bind there. The end result is increased sodium and water excretion into the urine, and potassium reabsorption. Aldosterone antagonists are referred to as <term class="no-emphasis" id="term-00028">potassium-sparing diuretics</term>.</para>
<para id="para-00035">MRA medications have been found to reduce the risk of all-cause mortality in clients with heart failure (Heidenreich et al., 2022).</para>
<para id="para-00036"><link target-id="table-00006" document="m00295"/> lists the two MRAs used in heart failure and typical routes and dosing for adult clients.</para>
<table class="vertically-tight full-width" id="table-00006">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="2*"/>
<thead>
<row>
<entry valign="middle" align="center"><span class="blue-text">Drug</span></entry>
<entry valign="middle" align="center"><span class="blue-text">Routes and Dosage Ranges</span></entry>
</row>
</thead>
<tbody>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00029">Spironolactone</term><newline/>
(<term class="no-emphasis" id="term-00030">Aldactone</term>)</entry>
<entry valign="top" align="left">12.5–25 mg orally daily; maximum dose: 50 mg daily.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00031">Eplerenone</term><newline/>
(<term class="no-emphasis" id="term-00032">Inspra</term>)</entry>
<entry valign="top" align="left">25–50 mg orally daily.</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Emphasis Table: MRAs</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
<section id="sect-00013">
<title>Adverse Effects and Contraindications</title>
<para id="para-00037">Adverse effects of MRAs include hyperkalemia, hypotension, worsening renal failure, electrolyte abnormalities, and gynecomastia (breast enlargement and/or sensitivity).</para>
<para id="para-00038">MRAs should not be taken during pregnancy. Because MRAs cause potassium retention, they should not be used by clients who have kidney disease. MRAs must be used carefully with other medications, such as ACE inhibitors and ARBs, that may cause hyperkalemia.</para>
<para id="para-00039"><link target-id="table-00007" document="m00295"/> is a drug prototype table for MRAs featuring spironolactone. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00007">
<tgroup cols="2">
<colspec colnum="1" colname="col1" colwidth="1*"/>
<colspec colnum="2" colname="col2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top">
<emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
Mineralocorticoid receptor antagonist (MRA)<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
Binds to receptors in the nephron so that aldosterone is not able to bind, which leads to increased diuresis</entry>
<entry valign="top">
<emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
12.5–25 mg orally daily; maximum dose: 50 mg daily.</entry>
</row>
<row>
<entry valign="top"><emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
Heart failure<newline/>
Hypertension<newline/>
Edema associated with hepatic cirrhosis or nephrotic syndrome<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
Diuresis</entry>
<entry valign="top">
<emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
Agents that increase serum potassium<newline/>
Lithium (increased risk for lithium toxicity)<newline/>
NSAIDs<newline/>
Digoxin<newline/>
Aspirin (may reduce the efficacy of spironolactone)<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
No significant interactions</entry>
</row>
<row>
<entry valign="top">
<emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
Hyperkalemia<newline/>
Hypotension<newline/>
Worsening renal failure<newline/>
Electrolyte abnormalities<newline/>
Gynecomastia</entry>
<entry valign="top">
<emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
Hyperkalemia<newline/>
Addison’s disease<newline/>
Pregnancy<newline/>
Concomitant use of eplerenone</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype Table: Spironolactone</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>

<note class="safety-alert" id="note-00008">
<title>MRAs</title>
<para id="para-00040">MRAs can cause significant hyperkalemia. The client should have their serum electrolytes monitored regularly while taking MRAs. If hyperkalemia occurs, the drug may have to be discontinued.</para>
</note>
</section>
<section id="sect-00014">
<title>Nursing Implications</title>
<para id="para-00041">The nurse should do the following for clients who are taking MRAs:</para>
<list id="list-00008">
<item>Monitor the client for medication and/or food interactions. </item>
<item>Monitor the client for adverse effects, including electrolyte imbalances and alteration renal function. </item>
<item>Provide client teaching regarding the drug and when to call the health care provider. See below for client teaching guidelines.</item>
</list>
<note class="client-teaching" id="note-00009">
<para id="para-00042"><emphasis effect="bold">The client taking an MRA should:</emphasis></para>
<list list-type="bulleted" id="list-00009">
<item>Avoid foods high in potassium and salt substitutes (because these are high in potassium) due to the aldosterone release. </item>
<item>Notify their provider if they are taking an ACE inhibitor, ARB, or other potassium-sparing drugs.</item>
<item>Notify their health care provider if pregnant, planning on getting pregnant, or breastfeeding prior to starting an MRA.</item>
<item>Notify their health care provider about breast enlargement and/or tenderness.</item>
<item>Notify their health care provider about symptoms such as dizziness, lightheadedness, or fainting because these could be related to low blood pressure.</item>
</list>
</note>
<note class="black-box" id="note-00010">
<para id="para-00043"><emphasis effect="bold">Drugs Affecting the Renin-Angiotensin-Aldosterone System</emphasis></para>
<para id="para-00044">Fetal toxicity can occur when taking <emphasis effect="bold">ACE inhibitors</emphasis> during the second and third trimesters of pregnancy or when taking <emphasis effect="bold">ARBs</emphasis> or <emphasis effect="bold">ARNIs</emphasis> during pregnancy.</para>
</note>
</section>
</section>
</content>
<glossary>
<definition id="def-00001"><term>angiotensin I</term> <meaning>a protein in blood that promotes aldosterone secretion and raises blood pressure </meaning></definition>
<definition id="def-00002"><term>angiotensin II</term> <meaning>a protein in the blood that causes the muscular walls of the arterioles to constrict and narrow, thereby increasing blood pressure </meaning></definition>
<definition id="def-00003"><term>angiotensin II receptor blocker (ARB)</term> <meaning>a classification of drugs that bind to and inhibit angiotensin II type I receptors </meaning></definition>
<definition id="def-00004"><term>angiotensin-converting enzyme (ACE) inhibitor</term> <meaning>a classification of drugs that block the body’s production of angiotensin II; causes vasoconstriction and inhibits the reuptake of norepinephrine, which stimulates catecholamine release </meaning></definition>
<definition id="def-00005"><term>angiotensin receptor/neprilysin inhibitor (ARNI)</term> <meaning>a classification of drugs that bind to and inhibit angiotensin II type I receptors and inhibit the breakdown of BNP</meaning></definition>
<definition id="def-00006"><term>mineralocorticoid receptor antagonist (MRA)</term> <meaning>a classification of drugs that cause diuresis and other effects by binding to receptors in the nephron so that aldosterone is not able to affect it and cause sodium and water reabsorption</meaning></definition>
<definition id="def-00007"><term>renin-angiotensin-aldosterone system (RAAS)</term> <meaning>a compensatory mechanism the body activates during hypotension (when the blood pressure is low) </meaning></definition>
</glossary>
</document>